Collinsella aerofaciens as a predictive marker of response to probiotic treatment in non-constipated irritable bowel syndrome

References

• Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R. Bowel Disorders. Gastroenterology. 2016. doi:10.1053/j.gastro.2016.02.031.
   Web of Science ®Google Scholar
• Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2006;130(1):34–16. doi: 10.1053/j.gastro.2005.09.031.
   PubMed Web of Science ®Google Scholar
• Dunlop SP, Coleman NS, Blackshaw E, Perkins AC, Singh G, Marsden CA, Spiller RC. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol. 2005;3(4):349–357. doi: 10.1016/s1542-3565(04)00726-8.
   PubMed Web of Science ®Google Scholar
• Simren M, Stotzer PO, Sjovall H, Abrahamsson H, Bjornsson ES. Abnormal levels of neuropeptide Y and peptide YY in the colon in irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2003;15:55–62. doi:10.1097/00042737-200301000-00010.
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Gilja OH, Gundersen D, Hatlebakk JG, Hausken T. Endocrine cells in the ileum of patients with irritable bowel syndrome. World J Gastroenterol. 2014;20(9):2383–2391. doi: 10.3748/wjg.v20.i9.2383.
   PubMed Web of Science ®Google Scholar
• Barbara G, Wang B, Stanghellini V, de Giorgio R, Cremon C, Di Nardo G, Trevisani M, Campi B, Geppetti P, Tonini M, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology. 2007;132(1):26–37. doi:10.1053/j.gastro.2006.11.039.
   PubMed Web of Science ®Google Scholar
• Chong PP, Chin VK, Looi CY, Wong WF, Madhavan P, Yong VC. The microbiome and irritable bowel syndrome - a review on the pathophysiology, Current research and future therapy. Front Microbiol. 2019;10:1136. doi:10.3389/fmicb.2019.01136.
   PubMed Web of Science ®Google Scholar
• Piche T, Barbara G, Aubert P, Bruley des Varannes S, Dainese R, Nano JL, Cremon C, Stanghellini V, De Giorgio R, Galmiche JP, et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut. 2009;58(2):196–201. doi:10.1136/gut.2007.140806.
   PubMed Web of Science ®Google Scholar
• Shaikh SD, Sun N, Canakis A, Park WY, Weber HC. Irritable bowel syndrome and the gut microbiome: a comprehensive review. J Clin Med. 2023;12(7):2558. doi: 10.3390/jcm12072558.
   PubMed Web of Science ®Google Scholar
• Drossman DA, Hasler WL. Rome IV—functional GI disorders: disorders of gut-brain interaction. Gastroenterology. 2016;150(6):1257–1261. doi: 10.1053/j.gastro.2016.03.035.
   PubMed Web of Science ®Google Scholar
• Bhattarai Y, Muniz Pedrogo DA, Kashyap PC. Irritable bowel syndrome: a gut microbiota-related disorder? Am J Physiol Gastrointest Liver Physiol. 2017;312:G52–G62. doi:10.1152/ajpgi.00338.2016.
   PubMed Web of Science ®Google Scholar
• Milner E, Stevens B, An M, Lam V, Ainsworth M, Dihle P, Stearns J, Dombrowski A, Rego D, Segars K. Utilizing probiotics for the prevention and treatment of gastrointestinal diseases. Front Microbiol. 2021;12:689958. doi: 10.3389/fmicb.2021.689958.
   PubMed Web of Science ®Google Scholar
• Andriulli A, Neri M, Loguercio C, Terreni N, Merla A, Cardarella MP, Federico A, Chilovi F, Milandri GL, De Bona M, et al. Clinical trial on the efficacy of a new symbiotic formulation, flortec, in patients with irritable bowel syndrome: a multicenter, randomized study. J Clin Gastroenterol. 2008;42(Supplement 3):S218–S23. doi:10.1097/MCG.0b013e31817fadd6.
   PubMedGoogle Scholar
• McFarland LV, Karakan T, Karatas A. Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. EClinicalMedicine. 2021;41:101154. doi:10.1016/j.eclinm.2021.101154.
   PubMedGoogle Scholar
• Ford AC, Harris LA, Lacy BE, Quigley EMM, Moayyedi P. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2018;48(10):1044–1060. doi: 10.1111/apt.15001.
   PubMed Web of Science ®Google Scholar
• Arioli S, Koirala R, Taverniti V, Fiore W, Guglielmetti S. Quantitative recovery of viable Lactobacillus paracasei CNCM I-1572 (L. casei DG®) after gastrointestinal passage in healthy adults. Front Microbiol. 2018;9:1720. doi: 10.3389/fmicb.2018.01720.
   PubMed Web of Science ®Google Scholar
• Radicioni M, Koirala R, Fiore W, Leuratti C, Guglielmetti S, Arioli S. Survival of L. casei DG® (Lactobacillus paracasei CNCMI1572) in the gastrointestinal tract of a healthy paediatric population. Eur J Nutr. 2019;58(8):3161–3170. doi: 10.1007/s00394-018-1860-5.
   PubMed Web of Science ®Google Scholar
• Ferrario C, Taverniti V, Milani C, Fiore W, Laureati M, De Noni I, Stuknyte M, Chouaia B, Riso P, Guglielmetti S. Modulation of fecal Clostridiales bacteria and butyrate by probiotic intervention with Lactobacillus paracasei DG varies among healthy adults. J Nutr. 2014;144:1787–1796. doi: 10.3945/jn.114.197723.
   PubMed Web of Science ®Google Scholar
• Bretto E, D’Amico F, Fiore W, Tursi A, Danese S. Lactobacillus paracasei CNCM I 1572: a promising Candidate for management of colonic diverticular disease. J Clin Med. 2022;11(7):11. doi: 10.3390/jcm11071916.
   Web of Science ®Google Scholar
• Cremon C, Guglielmetti S, Gargari G, Taverniti V, Castellazzi AM, Valsecchi C, Tagliacarne C, Fiore W, Bellini M, Bertani L, et al. Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: a pilot randomized clinical trial. United Eu Gastroenterol J. 2018;6(4):604–613. doi:10.1177/2050640617736478.
   PubMed Web of Science ®Google Scholar
• Ford AC, Sperber AD, Corsetti M, Camilleri M. Irritable bowel syndrome. Lancet. 2020;396:1675–1688. doi: 10.1016/S0140-6736(20)31548-8.
   PubMed Web of Science ®Google Scholar
• Kim JH, Lin E, Pimentel M. Biomarkers of irritable bowel syndrome. J Neurogastroenterol Motil. 2017;23(1):20–26. doi: 10.5056/jnm16135.
   PubMed Web of Science ®Google Scholar
• Zmora N, Zilberman-Schapira G, Suez J, Mor U, Dori-Bachash M, Bashiardes S, Kotler E, Zur M, Regev-Lehavi D, Brik R-Z, et al. Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. Cell. 2018;174(6):1388–405.e21. doi:10.1016/j.cell.2018.08.041.
   PubMed Web of Science ®Google Scholar
• Vervier K, Moss S, Kumar N, Adoum A, Barne M, Browne H, Kaser A, Kiely CJ, Neville BA, Powell N, et al. Two microbiota subtypes identified in irritable bowel syndrome with distinct responses to the low FODMAP diet. Gut. 2022;71(9):1821–1830. doi:10.1136/gutjnl-2021-325177.
   PubMedGoogle Scholar
• Duan R, Zhu S, Wang B, Duan L. Alterations of gut microbiota in patients with irritable bowel syndrome based on 16S rRNA-targeted sequencing: a systematic review. Clin Transl Gastroenterol. 2019;10(2):e00012. doi: 10.14309/ctg.0000000000000012.
   PubMedGoogle Scholar
• Maharshak N, Ringel Y, Katibian D, Lundqvist A, Sartor RB, Carroll IM, Ringel-Kulka T. Fecal and mucosa-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Dig Dis Sci. 2018;63(7):1890–1899. doi: 10.1007/s10620-018-5086-4.
   PubMed Web of Science ®Google Scholar
• Altomare A, Di Rosa C, Imperia E, Emerenziani S, Cicala M, Guarino MPL. Diarrhea predominant-Irritable Bowel Syndrome (IBS-D): effects of different nutritional patterns on intestinal dysbiosis and symptoms. Nutrients. 2021;13(5):1506. doi: 10.3390/nu13051506.
   PubMed Web of Science ®Google Scholar
• Gargari G, Taverniti V, Gardana C, Cremon C, Canducci F, Pagano I, Barbaro MR, Bellacosa L, Castellazzi AM, Valsecchi C, et al. Fecal Clostridiales distribution and short-chain fatty acids reflect bowel habits in irritable bowel syndrome. Environ Microbiol. 2018;20:3201–3213. doi:10.1111/1462-2920.14271.
   PubMed Web of Science ®Google Scholar
• Taras D, Simmering R, Collins MD, Lawson PA, Blaut M. Reclassification of Eubacterium formicigenerans Holdeman and Moore 1974 as Dorea formicigenerans gen. nov., comb. nov., and description of Dorea longicatena sp. nov., isolated from human faeces. Int J Syst Evol Microbiol. 2002;52:423–428. doi: 10.1099/00207713-52-2-423.
   PubMed Web of Science ®Google Scholar
• Kageyama A, Benno YC, Omura S. Bergey’s manual of systematics of archaea and bacteria. J Gen Appl Microbiol. 2007;53:1–6. doi: 10.2323/jgam.53.1.
   PubMedGoogle Scholar
• Scaldaferri F, Nardone O, Lopetuso LR, Petito V, Bibbo S, Laterza L, Gerardi V, Bruno G, Scoleri I, Diroma A, et al. Intestinal gas production and gastrointestinal symptoms: from pathogenesis to clinical implication. Eur Rev Med Pharmacol Sci. 2013;17 Suppl 2(Suppl 2):2–10.
   PubMedGoogle Scholar
• Jahng J, Jung IS, Choi EJ, Conklin JL, Park H. The effects of methane and hydrogen gases produced by enteric bacteria on ileal motility and colonic transit time. Neurogastroenterol Motil. 2012;24(2):185–90, e92. doi: 10.1111/j.1365-2982.2011.01819.x.
   PubMed Web of Science ®Google Scholar
• Kumar S, Misra A, Ghoshal UC. Patients with irritable bowel syndrome exhale more hydrogen than healthy subjects in fasting state. J Neurogastroenterol Motil. 2010;16(3):299–305. doi: 10.5056/jnm.2010.16.3.299.
   PubMedGoogle Scholar
• Lee SH, Cho DY, Joo NS, Kim KN. Effect of eradicating hydrogen-forming small intestinal bacterial overgrowth with rifaximin on body weight change. Med. 2019;98(51):e18396. doi: 10.1097/MD.0000000000018396.
   PubMed Web of Science ®Google Scholar
• Ghoshal UC, Kumar S, Mehrotra M, Lakshmi C, Misra A. Frequency of small intestinal bacterial overgrowth in patients with irritable bowel syndrome and chronic non-specific diarrhea. J Neurogastroenterol Motil. 2010;16(1):40–46. doi: 10.5056/jnm.2010.16.1.40.
   PubMedGoogle Scholar
• Afolayan AO, Adebusoye LA, Cadmus EO, Ayeni FA. Insights into the gut microbiota of Nigerian elderly with type 2 diabetes and non-diabetic elderly persons. Heliyon. 2020;6(5):e03971. doi: 10.1016/j.heliyon.2020.e03971.
   PubMed Web of Science ®Google Scholar
• Alam MT, Amos GCA, Murphy ARJ, Murch S, Wellington EMH, Arasaradnam RP. Microbial imbalance in inflammatory bowel disease patients at different taxonomic levels. Gut Pathog. 2020;12(1):1. doi: 10.1186/s13099-019-0341-6.
   PubMed Web of Science ®Google Scholar
• Schirmer M, Smeekens SP, Vlamakis H, Jaeger M, Oosting M, Franzosa EA, Ter Horst R, Jansen T, Jacobs L, Bonder MJ, et al. Linking the human gut microbiome to inflammatory cytokine production capacity. Cell. 2016;167(4):1125–36 e8. doi:10.1016/j.cell.2016.10.020.
   PubMed Web of Science ®Google Scholar
• Crost EH, Tailford LE, Le Gall G, Fons M, Henrissat B, Juge N, de Crécy-Lagard V. Utilisation of mucin glycans by the human gut symbiont Ruminococcus gnavus is strain-dependent. PLoS ONE. 2013;8(10):e76341. doi: 10.1371/journal.pone.0076341.
   PubMed Web of Science ®Google Scholar
• Companys J, Gosalbes MJ, Pla-Paga L, Calderon-Perez L, Llaurado E, Pedret A, Valls RM, Jimenez-Hernandez N, Sandoval-Ramirez BA, Del Bas JM, et al. Gut microbiota profile and its association with clinical variables and dietary intake in overweight/obese and lean subjects: a cross-sectional study. Nutrients. 2021;13(6):2032. doi:10.3390/nu13062032.
   PubMed Web of Science ®Google Scholar
• Gallardo-Becerra L, Cornejo-Granados F, Garcia-Lopez R, Valdez-Lara A, Bikel S, Canizales-Quinteros S, Lopez-Contreras BE, Mendoza-Vargas A, Nielsen H, Ochoa-Leyva A. Metatranscriptomic analysis to define the secrebiome, and 16S rRNA profiling of the gut microbiome in obesity and metabolic syndrome of Mexican children. Microb Cell Fact. 2020;19(1):61. doi: 10.1186/s12934-020-01319-y.
   PubMed Web of Science ®Google Scholar
• Kulkarni P, Devkumar P, Chattopadhyay I. Could dysbiosis of inflammatory and anti-inflammatory gut bacteria have an implications in the development of type 2 diabetes? A pilot investigation. BMC Res Notes. 2021;14(1):52. doi: 10.1186/s13104-021-05466-2.
   PubMed Web of Science ®Google Scholar
• Petersen AO, Jokinen M, Plichta DR, Liebisch G, Gronwald W, Dettmer K, Oefner PJ, Vlamakis H, Chung DC, Ranki A, et al. Cytokine-specific autoantibodies shape the gut microbiome in autoimmune polyendocrine syndrome type 1. J Allergy Clin Immunol. 2021;148(3):876–888. doi:10.1016/j.jaci.2021.03.025.
   PubMed Web of Science ®Google Scholar
• Shapiro J, Cohen NA, Shalev V, Uzan A, Koren O, Maharshak N. Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls. J Dermatol. 2019;46:595–603. doi: 10.1111/1346-8138.14933.
   PubMed Web of Science ®Google Scholar
• Chen J, Wright K, Davis JM, Jeraldo P, Marietta EV, Murray J, Nelson H, Matteson EL, Taneja V. An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis. Genome Med. 2016;8(1):43. doi: 10.1186/s13073-016-0299-7.
   PubMed Web of Science ®Google Scholar
• Herrnberger L, Seitz R, Kuespert S, Bosl MR, Fuchshofer R, Tamm ER. Lack of endothelial diaphragms in fenestrae and caveolae of mutant plvap-deficient mice. Histochem Cell Biol. 2012;138(5):709–724. doi: 10.1007/s00418-012-0987-3.
   PubMed Web of Science ®Google Scholar
• Rantakari P, Auvinen K, Jappinen N, Kapraali M, Valtonen J, Karikoski M, Gerke H, Iftakhar EKI, Keuschnigg J, Umemoto E, et al. The endothelial protein PLVAP in lymphatics controls the entry of lymphocytes and antigens into lymph nodes. Nat Immunol. 2015;16(4):386–396. doi:10.1038/ni.3101.
   PubMed Web of Science ®Google Scholar
• Spadoni I, Pietrelli A, Pesole G, Rescigno M. Gene expression profile of endothelial cells during perturbation of the gut vascular barrier. Gut Microbes. 2016;7(6):540–548. doi: 10.1080/19490976.2016.1239681.
   PubMed Web of Science ®Google Scholar
• Lee SH, Kim KN, Kim KM, Joo NS. Irritable bowel syndrome may be associated with elevated alanine aminotransferase and metabolic syndrome. Yonsei Med J. 2016;57(1):146–152. doi: 10.3349/ymj.2016.57.1.146.
   PubMed Web of Science ®Google Scholar
• Wu S, Yuan C, Yang Z, Liu S, Zhang Q, Zhang S, Zhu S. Non-alcoholic fatty liver is associated with increased risk of irritable bowel syndrome: a prospective cohort study. BMC Med. 2022;20(1):262. doi: 10.1186/s12916-022-02460-8.
   PubMed Web of Science ®Google Scholar
• Tornavaca O, Chia M, Dufton N, Almagro LO, Conway DE, Randi AM, Schwartz MA, Matter K, Balda MS. ZO-1 controls endothelial adherens junctions, cell–cell tension, angiogenesis, and barrier formation. J Cell Biol. 2015;208(6):821–838. doi: 10.1083/jcb.201404140.
   PubMed Web of Science ®Google Scholar
• Gupta VK, Paul S, Dutta DC. Geography, ethnicity or subsistence-specific variations in human microbiome composition and diversity. Front Microbiol. 2017;8:1162. doi: 10.3389/fmicb.2017.01162.
   PubMed Web of Science ®Google Scholar
• Lembo AJ, Lacy BE, Zuckerman MJ, Schey R, Dove LS, Andrae DA, Davenport JM, McIntyre G, Lopez R, Turner L, et al. Eluxadoline for irritable bowel syndrome with diarrhea. N Engl J Med. 2016;374:242–253. doi:10.1056/NEJMoa1505180.
   PubMed Web of Science ®Google Scholar
• Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, Huttenhower C. Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12(6):R60. doi: 10.1186/gb-2011-12-6-r60.
   PubMed Web of Science ®Google Scholar